re QURE's HemoB trial (news from 6/22) | SGMO Message Board Posts


Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  158512 of 159355  at  6/24/2021 9:56:25 AM  by

Watsonncrick

The following message was updated on 6/24/2021 9:59:24 AM.

 In response to msg 158509 by  retired@49
view thread

Re: re QURE's HemoB trial (news from 6/22)

  
 Also points to a potential advantage for achieving shorter duration from administration to peak factor activity levels & subsequent steady-state i.e. the clock can start earlier in terms of the 52-week period to generate primary evidence of durability.
 
Of course, we'll have to wait and see what is ultimately determined by FDA for HemoA versus this HemoB program, but again, if Hemo A were to be treated consistent w/ this announcement by Uniqure then...
 
  • it points to a potential advantage for having a short/the shortest duration from time of administration to achieving peak levels of factor activity for HemoA gene therapy.
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 16  
   Views: 0 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
158513 Re: re QURE's HemoB trial (news from 6/22) egomaniakos 1 6/24/2021 9:58:16 AM


Financial Market Data provided by
.
Loading...